Hormone therapy for postmenopausal women

Linda Brent, PhD

Executive Director, Parsemus Foundation

Evidence is mounting that hormone therapy (HT) after menopause is not associated with increased risks, despite earlier concerns. A recent meta-analysis of a number of studies that is being presented at the Endocrine Society’s meeting in San Diego found no statistically significant relationship between HT and death due to any reason, or death due to heart attack, breast cancer or stroke. The investigators from the Mayo Clinic indicated in a press release that the data should help to allay concerns from women about treating symptoms of menopause. For more information on Parsemus Foundation’s role in furthering our understanding of hormones and breast cancer, check out the Questioning Aromatase Inhibitors page.

We’re sorry, you are not eligible for the nationwide COVID-OUT or ACTIV-6 studies, but you may be eligible for other federal trials:

And if you don’t find a match there, this slightly more complex clinical trials finder includes studies sponsored by companies as well:

Trials Today